This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Celsion

At a European thyroid research meeting last September, researchers reported that ATC patients treated with a combination of zybrestat and chemotherapy demonstrated a median overall survival of 5.1 months compared to a median overall survival of 4.1 months for similar patients treated with chemotherapy alone. While trending in the right direction, this survival benefit was not statistically significant.

Oxigene has been up front about the regulatory shortcomings of the "FACT" study. In March, the FDA told Oxigene that a second phase III study with a survival endpoint would be necessary before Zybrestat could be submitted for approval as a treatment for ATC.

This pretty much diminishes any news value from another update of the old study at next month's ASCO meeting.

The second clinical update at next month's ASCO will come from the phase II "FALCON" study that compares Zybrestat, Roche's Avastin plus chemotherapy against Avastin and chemotherapy in patients with advanced non-small cell lung cancer.

Again, Oxigene has presented data from this study previously. The last update was in November, when Oxigene reported the median time to progression for patients treated with the Zybrestat regimen was 9.5 months compared to 8.8 months for the control arm. The difference was not statistically significant and at less than a month's difference, likely not clinically meaningful.

The "FALCON" study is designed to report out an overall survival analysis, but it's not clear whether that's ready for this year's ASCO meeting.

For those wishing to look up the Zybrestat ASCO abstracts on May 18 when they're posted online, the "FACT" study is abstract No. 5502 while the "FALCON" study is abstract No. 7559.

@kevinmcgreevy tweets, "I know things are bad at $alth, but $mnkd has 2x the market cap now?!? Is it that bad?"

Geesh, when you put it that way, you're absolutely right. Allos Therapeutics (ALTH) is way better off than MannKind (MNKD). Then again, there are few drug or biotech stocks in sorrier shape than MannKind, so are you really damning Allos with faint praise?

Kevin's question riffs off a Twitter debate I had with a few people Tuesday night following the release of Allos' first-quarter results (bad) and the announcement of a deal with Mundipharma for European marketing rights to Folytn, Allos' lymphoma drug (good).
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OPTR $0.00 0.00%
CLSN $1.25 0.00%
DCTH $0.28 0.00%
EXEL $4.54 0.00%
INCY $71.00 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs